ReviewESMO real world data and digital oncology2026
Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review.
Review in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Defining, measuring, and reporting exposure in real-world data are important for the valid generation and interpretation of real-world evidence (RWE). This is especially challenging for oncology medicines, due to complicated treatment regimens and adjustments in dose and/or schedule. This scoping review aims to assess the reporting of drug exposure definitions for oncology medicines in RWE studies, using colorectal cancer (CRC) as a case study. Methods: We searched PubMed and Embase for RWE studies assessing clinical outcomes of cyclically administered oncology medicines in patients with CRC, published in 2023-2024. We extracted publication characteristics, study characteristics, and exposure variables. We calculated a drug exposure reporting score (0-7), composed of active substance, dose, dosing schedule, number of cycles, treatment episode length, and drug exposure start/end. We exploratively compared characteristics of studies with a high and low score. Results: Of the 61 included studies, 59% used hospital data, and 36.1% used drug administration data. Most studies (83.6%) reported the start of drug exposure, and 34.4% reported the end of drug exposure. Median drug exposure reporting score was 3.0 (interquartile range 2.0-4.0). Studies with a high score were 4.6 times more often published in an oncology journal and reported use of guidelines for observational studies 1.8 times more often than studies with a low score. Conclusion: Definitions of drug exposure are often underreported in RWE studies on oncology medicines. Lack of clarity concerning oncological drug exposure complicates the assessment of the methodological quality and reproducibility and may affect the interpretation of the association between oncology medicines and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.